STAT's Adam Feuerstein said via Twitter, "Not that anyone trading cares, but today's $LPCN liver fat (NASH? NAFLD? Something else?) data are worse than the data previously disclosed in January. Also, wow, so many changes to endpoint definitions. Carry on...." Shares of Lipocine are up 34c, or 16%, to $2.52 in premarket trading.
https://thefly.com/landingPageNews.php?id=2877810
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.